IRS1, insulin receptor substrate 1, 3667

N. diseases: 233; N. variants: 15
Disease: Mammary Neoplasms ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 Biomarker group BEFREE CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. 31468695 2019
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 Biomarker group BEFREE IRS1 has been implicated in the proliferation and survival of breast tumor cells. 29685905 2018
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 Biomarker group BEFREE Analysis of breast tumor cell lines showed that REST directly represses IRS1, and cells lacking REST have increased levels of IRS1 mRNA and protein. 26100015 2015
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 Biomarker group BEFREE The regulation of unique subsets of Akt substrates by Irs-1 and Irs-2 may explain their non-redundant roles in mammary tumor biology. 24811175 2014
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group BEFREE IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. 23562473 2013
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group BEFREE This novel interaction may have clinical relevance, as immunohistochemical analysis of a small ER+ breast tumour series revealed significant positive correlations between phosphorylated IRS-1 Y612 expression and total erbB3, phosphorylated Akt and Ki-67 expression. 21939528 2011
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 GeneticVariation group LHGDN Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. 17051426 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 Biomarker group BEFREE Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. 17030605 2006
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group LHGDN Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. 17030605 2006
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 Biomarker group LHGDN Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells. 12354757 2002
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group LHGDN Nitric oxide regulates oestrogen-activated signalling pathways at multiple levels through cyclic GMP-dependent recruitment of insulin receptor substrate 1. 11978177 2002
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group BEFREE Finally, we have shown that high IRS-1 expression is an indicator of early disease recurrence in ER-positive human primary breast tumors. 10319328 1999
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group BEFREE Thus, overexpression of IRS-1 in breast tumors could contribute to the development of antiestrogen resistance. 10188734 1999